326 related articles for article (PubMed ID: 23460074)
1. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Navarro-Millán I; Charles-Schoeman C; Yang S; Bathon JM; Bridges SL; Chen L; Cofield SS; Dell'Italia LJ; Moreland LW; O'Dell JR; Paulus HE; Curtis JR
Arthritis Rheum; 2013 Jun; 65(6):1430-8. PubMed ID: 23460074
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
3. Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.
Rodriguez-Jimenez NA; Garcia-Gonzalez CE; Ayala-Lopez KP; Trujillo-Hernandez B; Aguilar-Chavez EA; Rocha-Muñoz AD; Vasquez-Jimenez JC; Olivas-Flores E; Salazar-Paramo M; Corona-Sanchez EG; Vazquez-Del Mercado M; Varon-Villalpando E; Cota-Sanchez A; Cardona-Muñoz EG; Gamez-Nava JI; Gonzalez-Lopez L
Biomed Res Int; 2014; 2014():510305. PubMed ID: 25243145
[TBL] [Abstract][Full Text] [Related]
4. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
O'Dell JR; Curtis JR; Mikuls TR; Cofield SS; Bridges SL; Ranganath VK; Moreland LW;
Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
[TBL] [Abstract][Full Text] [Related]
5. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.
Charles-Schoeman C; Wang X; Lee YY; Shahbazian A; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; O'Dell J; Bathon JM; Paulus H; Bridges SL; Curtis JR
Arthritis Rheumatol; 2016 Mar; 68(3):577-86. PubMed ID: 26606398
[TBL] [Abstract][Full Text] [Related]
6. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Charles-Schoeman C; Yin Lee Y; Shahbazian A; Wang X; Elashoff D; Curtis JR; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; Paulus H; O'Dell J; Bathon J; Louis Bridges S; Reddy ST
Arthritis Rheumatol; 2017 Jan; 69(1):46-57. PubMed ID: 27483410
[TBL] [Abstract][Full Text] [Related]
7. Etanercept for the treatment of rheumatoid arthritis.
Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
[TBL] [Abstract][Full Text] [Related]
8. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Curtis JR; McVie T; Mikuls TR; Reynolds RJ; Navarro-Millán I; O'Dell J; Moreland LW; Bridges SL; Ranganath VK; Cofield SS
J Rheumatol; 2013 May; 40(5):572-8. PubMed ID: 23588939
[TBL] [Abstract][Full Text] [Related]
9. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.
Maska LB; Sayles HR; O'Dell JR; Curtis JR; Bridges SL; Moreland LW; Cofield SS; Mikuls TR
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1804-10. PubMed ID: 22730343
[TBL] [Abstract][Full Text] [Related]
10. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
Emery P; Breedveld F; van der Heijde D; Ferraccioli G; Dougados M; Robertson D; Pedersen R; Koenig AS; Freundlich B;
Arthritis Rheum; 2010 Mar; 62(3):674-82. PubMed ID: 20187135
[TBL] [Abstract][Full Text] [Related]
11. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
12. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Emery P; Breedveld FC; Hall S; Durez P; Chang DJ; Robertson D; Singh A; Pedersen RD; Koenig AS; Freundlich B
Lancet; 2008 Aug; 372(9636):375-82. PubMed ID: 18635256
[TBL] [Abstract][Full Text] [Related]
15. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.
Liao KP; Rist P; Giles J; Santacroce L; Connelly MA; Glynn RJ; Ridker P; Tawakol A; Bathon J; Solomon DH
Arthritis Res Ther; 2024 Jun; 26(1):123. PubMed ID: 38915065
[TBL] [Abstract][Full Text] [Related]
16. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
17. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
van Vollenhoven RF; Chatzidionysiou K
Nat Rev Rheumatol; 2013 Sep; 9(9):510-2. PubMed ID: 23897440
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
20. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
